Medtronic received market clearance from the Food and Drug Administration for its insertable cardiac monitor.
Clinicians insert the Reveal LINQ Insertable Cardiac Monitor in the upper left side of a patient's chest during a minimally invasive procedure. The implanted device allows clinicians to continuously monitor a patient's heartbeat for up to three years, according to a company news release.
The device uses wireless communication to upload device data, and patients can undergo MRIs while using the implanted device.
More articles on supply chain:
Patients often skip, delay or ration cancer treatments due to high drug costs: 5 takeaways
7 things to know about Dr. Scott Gottlieb's relationship with the drug industry
Mylan settles biosimilar patent dispute with Roche: 4 things to know